A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Valeria MerzCamilla ZecchettoFrancesca SimionatoAlessandro CavaliereSimona CasalinoMichele PavaranaSimone GiacopuzziMaria BencivengaAnna TomezzoliRaffaela SantoroVita FedeleSerena ContarelliIrene RossiSerena GiacomazziMartina PasquatoCristiana PiazzolaStefano MilleriGiovanni de ManzoniDavide Melisi

Published in: Therapeutic advances in medical oncology (2020)

2017-004522-14.

Keyphrases

phase iii
open label
phase ii
study protocol
epidermal growth factor receptor
clinical trial
metastatic breast cancer
placebo controlled
double blind